Unosi

• Essential to increase the use of generics in Europe to maintain comprehensive health care? (2012-01)

  B. Godman, M. Bennie, C. Baumgartel, L. Sović-Brkičić, T. Burkhardt, J. Furst, K. Garuoliene, M. Gomes, V. Marković Peković, A. Martin, C. Sermet, P. Skiold, M. van Woerkom, L. Vončina, L. Gustafsson, Essential to increase the use of generics in Europe to maintain comprehensive health care?, STED Journal, Vol. 13, No. 3S, pp. 5 - 20, Jan, 2012

• Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs (2013-05)

  R. Malmstrom, E. Digene, C. Baumgartel, M. Bennie, I. Bishop, A. Brzezinska, S. Campbell, A. Ferrario, A. Finlayson, J. Furst, K. Garuoliene, M. Gomes, I. Gutierrez-Ibarluzea, A. Haycox, K. Hviding, H. Herholz, M. Hoffman, S. Jan, J. Jones, R. Joppi, M. Kalaba, C. Kvalheim, O. Laius, I. Langner, J. Lonsdale, S. Loov, K. Malinowska, L. McCullagh, K. Paterson, V. Marković Peković, A. Martin, J. Piessnegger, G. Selke, C. Sermet, S. Simoens, C. Tulnay, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wilcock, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs, Frontiers in Pharmacology, Vol. 4, pp. 1 - 31, May, 2013

• Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs (2014-06)

  B. Godman, R. Malmstrom, E. Digene, S. Jayathissa, S. McTaggart, T. Cars, S. Alvarez-Madrazo, C. Baumgartel, A. Brzezinska, A. Bucsics, S. Campbell, I. Eriksson, A. Finlayson, J. Furst, K. Garuoliene, I. Gutierrez-Ibarluzea, K. Hviding, H. Herholz, R. Joppi, R. Joppi, M. Kalaba, O. Laius, K. Malinowska, H. Pedersen, V. Marković Peković, J. Piessnegger, G. Selke, C. Sermet, S. Spillane, D. Tomek, L. Vončina, V. Vlahović-Palčevski, J. Wale, M. Wladysiuk, M. van Woerkom, C. Zara, L. Gustafsson, Dabigatran - a continuing exemplar case history demonstrating the need for comprehensive models to optimize the utilization of new drugs, Frontiers in Pharmacology, Vol. 5, pp. 1 - 11, Jun, 2014

• Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future (2015-05)

  B. Godman, M. Wilcock, A. Martin, S. Bryson, C. Baumgartel, T. Bochenek, W. de Bruyn, L. Sović-Brkičić, M. D'Agata, A. Fogele, A. Coma Fuste, J. Fraeyman, J. Furst, K. Garuoliene, H. Herholz, M. Hoffman, S. Jayathissa, H. Kwon, I. Langner, M. Kalaba, E. Magnusson, E. Anderse Karlssen, O. Laius, V. Marković Peković, E. Magnusson, S. McTaggart, H. Pedersen, J. Piessnegger, A. Ringerud, G. Selke, C. Sermet, K. Schiffers, P. Skiold, D. Tomek, A. Viksna, A. Vitry, C. Zara, R. Malmstrom, Generic pregabalin; current situation and implications for health authorities, generics and biosimilars manufacturers in the future, Generics and Biosimilars Initiative Journal, Vol. 4, No. 3, pp. 125 - 135, May, 2015